I don't have access to the full text of the case series you've referenced, as only the title and URL were provided without the article content. However, the search results contain relevant information about dermatological and gastrointestinal adverse reactions associated with ocrelizumab in multiple sclerosis patients. ## Gastrointestinal Side Effects Common gastrointestinal adverse reactions include **diarrhea**, which appears frequently in clinical trial data[1][4]. Less commonly, ocrelizumab can cause **colitis** (inflammation of the colon), which presents as sudden or severe stomach pain, bloody diarrhea, fever, nausea, and vomiting and requires immediate medical attention[3][6]. ## Dermatological Side Effects **Skin reactions** are reported in patients receiving ocrelizumab[4]. These include: - Infusion-related skin manifestations: rash, hives, and itching[1][2][7] - **Skin infections** (cellulitis), which occur more frequently than with other treatments[2][5][9] - Herpes virus-associated infections, including cold sores or shingles[4][5] ## Clinical Context These adverse reactions occurred in ocrelizumab-treated MS patients during clinical trials, though the specific case series you referenced may describe individual patient presentations in greater detail. For comprehensive information about the particular cases discussed in that article, you would need to access the full case series directly.
Originaltitel: Dermatological and gastrointestinal adverse reactions in ocrelizumab treated patients with multiple sclerosis: a case series